Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.

Tang JC, Shen GB, Wang SM, Wan YS, Wei YQ.

Immunol Lett. 2014 Mar-Apr;158(1-2):159-66. doi: 10.1016/j.imlet.2013.12.019. Epub 2014 Jan 7.

PMID:
24406503
2.
3.

Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.

Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.

Cancer Res. 1993 Jan 1;53(1):106-11.

4.
5.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

6.

Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice.

Zhou R, He PL, Ren YX, Wang WH, Zhou RY, Wan H, Ono S, Fujiwara H, Zuo JP.

Cancer Sci. 2007 Jun;98(6):882-9. Epub 2007 Apr 13.

7.
8.

IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25 High CD4+ T cells.

Van Belle TL, Dooms H, Boonefaes T, Wei XQ, Leclercq G, Grooten J.

PLoS One. 2012;7(9):e45299. doi: 10.1371/journal.pone.0045299. Epub 2012 Sep 20.

9.

Hypothermic microenvironment plays a key role in tumor immune subversion.

Du G, Liu Y, Li J, Liu W, Wang Y, Li H.

Int Immunopharmacol. 2013 Oct;17(2):245-53. doi: 10.1016/j.intimp.2013.06.018. Epub 2013 Jul 3.

PMID:
23831011
10.

Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.

Cancer Res. 2005 Feb 1;65(3):1063-70.

11.

IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.

J Immunol. 1998 Feb 15;160(4):1742-9.

12.
13.

IL-28 elicits antitumor responses against murine fibrosarcoma.

Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M.

J Immunol. 2007 Apr 15;178(8):5086-98.

14.

All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.

Van YH, Lee WH, Ortiz S, Lee MH, Qin HJ, Liu CP.

Diabetes. 2009 Jan;58(1):146-55. doi: 10.2337/db08-1154. Epub 2008 Nov 4.

15.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

16.

Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice.

Molla Hassan AT, Hassan ZM, Moazzeni SM, Mostafaie A, Shahabi S, Ebtekar M, Hashemi SM.

Int Immunopharmacol. 2009 Nov;9(12):1381-6. doi: 10.1016/j.intimp.2009.08.008. Epub 2009 Aug 23.

PMID:
19706340
17.
18.
19.

Supplemental Content

Support Center